Article Figures & Data
Figures
- Fig. 1.
Serum SMRP concentrations in the population under investigation.
- Fig. 2.
A, Mesomark performance in differentiating between mesotheliomas and controls. B, Mesomark performance in differentiating between mesothelioma cases stage I to II and controls.
- Fig. 3.
Survival of mesothelioma patients according to serum SMRP levels.
Tables
- Table 1.
Characteristics of the study subjects
MM (n = 107) LC (n = 215) BRD (n = 130) Controls (n = 262)* Age (mean ± SD) 69.1 ± 9.9 65.4 ± 8.7 61.9 ± 10.5 53.9 ± 12.9 Sex     Male 89 (83.2%) 181 (84.2%) 114 (87.7%) 208 (79.4%)     Female 18 (16.8%) 34 (15.8%) 16 (12.3%) 54 (20.6%) Asbestos exposure     No exposure 19 (17.8%) 125 (58.1%) 19 (14.6%) 54 (20.6%)     Possible 5 (4.7%) 21 (9.8%) 2 (1.5%) 5 (1.9%)     Probable 5 (4.7%) 9 (4,2%) 3 (2.3%) —     Ascertained 77 (72%) 52 (24.2%) 105 (80.8%) 203 (77.5%)     NOS†1 (0.8%) 8 (3.7%) 1 (0.8%) — - Table 2.
Serum SMRP concentration (nmol/L) according to tumor morphology and stage
n (%) Mean ± SD Median (range) Mesothelioma 107 3.05 ± 5.6 1.42 (0.21-40.84) Histology     Epithelioid 72 (67.3) 3.72 ± 6.6 1.64 (0.21-40.84)     Mixed 7 (6.5) 1.69 ± 0.7 1.79 (0.48-2.74)     Sarcomatous 10 (9.4) 0.99 ± 0.6 1.02 (0.25-2.16)     Desmoplastic 3 (2.8) 0.5 ± 0.3 0.49 (0.23-0.77)     NOS* 15 (14.0) 2.37 ± 2.7 1.42 (0.42-10.32) Stage     I-II 43 (40.2) 2.24 ± 3.8 1.25 (0.23-25.10)     III-IV 45 (42.0) 3.93 ± 7.4 1.51 (0.21-40.84)     NOS* 19 (17.8) 2.83 ± 3.4 1.06 (0.35-10.32) Lung cancer 215 1.05 ± 1.1 0.82 (0.10-11.84) Histology     SCLC 5 (2.3) 0.96 ± 0.5 0.88 (0.44-1.65)     Adenocarcinomas 104 (48.4) 1.14 ± 1.4 0.84 (0.10-11.84)     Squamous 62 (28.8) 0.81 ± 0.5 0.70 (0.10-2.15)     NSCLC 26 (12.1) 0.97 ± 1.0 0.70 (0.16-5.37)     NOS* 18 (8.4) 1.44 ± 1.0 0.99 (0.53-3.61) Stage     I-II 43 (20.0) 1.04 ± 0.8 0.85 (0.22-3.91)     III-IV 145 (67.4) 1.06 ± 1.2 0.88 (0.10-11.84)     NOS* 27 (12.6) 1.01 ± 0.7 0.79 (0.22-3.41) BRD 130 0.76 ± 0.4 0.68 (0.12-2.47)     Asbestosis 12 (9.2) 0.70 ± 0.4 0.69 (0.15-1.74)     BRD, asbestos†46 (35.4) 0.75 ± 0.3 0.69 (0.20-1.58)     BRD, no asbestos‡ 31 (23.9) 0.72 ± 0.5 0.61 (0.20-2.17)     COPD§ 25 (19.2) 0.87 ± 0.5 0.70 (0.33-2.48)     Others∥ 16 (12.3) 0.81 ± 0.6 0.68 (0.12-1.83) Controls 262 0.76 ± 0.4 0.66 (0.16-2.36)     Healthy exposed 203 (77.5) 0.75 ± 0.4 0.64 (0.16-2.36)     Other controls¶ 59 (22.5) 0.81 ± 0.4 0.72 (0.20-2.18) ↵* Not otherwise specified.
↵†Pleural plaques, asbestos-related pleural thickening.
↵‡ Interstitial lung diseases, chronic pleuritis.
↵§ Chronic obstructive pulmonary disease.
↵∥ Pneumonia, tuberculosis, sarcoidosis, empyema, other benign non–asbestos-related lung and pleural disorders.
↵¶ Blood donors or patients hospitalized for orthopedic traumatic injury or eye disease.
- Table 3.
Efficacy of SMRP in differentiating between MM or LC and controls
Mesothelioma Lung cancer Cutoff TP FN FP TN Se Sp TP FN FP TN Se Sp 0.500 94 13 185 77 87.9 29.4 174 41 188 74 80.9 28.2 0.600 91 16 155 107 85.1 40.8 148 67 159 103 68.8 31.2 0.700 83 24 115 147 77.6 56.1 120 95 117 145 55.8 55.3 0.800 77 30 91 171 72.0 65.3 108 107 92 170 50.2 64.9 0.900 76 31 69 193 71.0 73.7 86 129 70 192 40.0 73.3 1.000 73 34 51 211 68.2 80.5 72 143 52 210 33.5 80.2 1.200 60 47 37 225 56.1 85.9 50 165 37 225 23.3 85.9 1.400 54 53 26 236 50.5 90.1 37 178 26 236 17.2 90.1 1.600 49 58 15 247 45.8 94.2 28 187 15 247 13.0 94.3 1.800 43 64 9 253 40.2 96.6 18 197 9 253 8.4 96.6 2.400 29 78 0 262 27.1 100.0 10 205 0 262 4.7 100.0 Abbreviations: TP, true positives; FN, false-negatives; FP, false-positives; TN, true negatives; Se, sensitivity; Sp, specificity.
Volume 13, Issue 17
